Next Generation Sequencing of Tumor Cells in Locally Advanced Pancreatic Adenocarcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

33 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-01

Study Completion Date

2021-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

All patients referring to the U.O .of Digestive Endoscopy of the Humanitas Hospital to undergo EUS with biopsy in the pre-treatment evaluation of locally advanced pancreatic adenocarcinoma, satisfying all the inclusion criteria and without any of the exclusion criteria, will be enrolled.

Patients will then undergo endoscopic procedures (EUS with biopsy) provided by good clinical practice in consideration of the suspected diagnosis for which they come to Investigator's attention.

Biopsy will be performed using a histology needle (22 G, Acquire, Boston Scientific, MA, United States). The obtained material will be processed in the Pathological Anatomy. A small part of this will be sent to the NGS analysis.

At the time of preparation for the examination, the patients will be asked for blood collection (10 ml of blood) in order to evaluate any circulating tumor cells that will be identified by SmartBioSurface technique (Tethis S.p.A) and analyzed by appropriate molecular markers and NGS.

The clinical evaluation of the patient will take place at 6 months from the date of the procedure, through telephone contact and / or outpatient visit.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC

NCT03032913

Pancreatic Ductal Adenocarcinoma (PDAC)

COMPLETED

Pancreatic Cancer Evolution Upon Treatment

NCT05195281

Pancreatic Cancer

RECRUITING NA

Role of Exosomes in Pancreatic Cancer Progression

NCT06777030

Pancreatic Cancer

RECRUITING

Pharmacotyping of Pancreatic Patient-derived Organoids

NCT05196334

Pancreatic Cancer

RECRUITING

Patient-derived Organoids Drug Screen in Pancreatic Cancer

NCT05351983

Pancreas Cancer Pancreas Neoplasm Pancreas Adenocarcinoma +3 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biopsy EUS guided

NGS Sequencing on Biopsy samples

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age\> 18 years,
* Signature of informed consent,
* Naïve patients with pancreatic adenocarcinoma (confirmed cito/ histologically), not subjected to previous treatments,
* Need to perform EUS with biopsy,
* Life expectancy over 6 months.

Exclusion Criteria

* Patients with non-primary pancreatic tumors, pancreatic neuroendocrine tumors or benign pancreatic masses
* Patients who have already undergone cancer treatment of any kind

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No